Mold-Tek Packaging Ltd

- No new equity fundraising is planned for the current or next financial year. - Pharma capacity expansion is being done primarily through brownfield expansion, with no new major CAPEX except land acquisition. - Land worth Rs. 11 crores was acquired recently for pharma expansion, indicating future greenfield expansion. - Brownfield expansions involve adding machinery and capacities gradually, expected to be operational by July-August next year. - Annual CAPEX for maintenance and expansions is projected at around Rs. 100-105 crores for the current year, down from previous years. - No mention of new debt fundraising; expansions appear to be funded through internal accruals or existing resources. - The company expects gradual capacity increases without sudden large capital inflows.

- Land acquisition for pharma expansion: 2.5 acres adjacent to Sultanpur unit, costing around Rs. 11 crores (Page 12). - Pharma capacity expansion: Brownfield increase to 2,500 tons planned progressively next financial year; no new capex counted for next year's projections (Page 12-13). - New pharma facility construction likely to start Dec-Jan; expected operational shape by next financial year's second half (Page 16). - CAPEX guidance: Around Rs. 100-105 crores expected for the current year, down from Rs. 130-140 crores in prior years (Page 11). - Maintenance CAPEX will continue, aligning close to depreciation (~Rs. 35-40 crores annually) (Page 12). - Paint segment capacity: Total capacity for ABG (paints) ~10,000 tons across 3 plants, currently at ~60-65% utilization (Page 7). - IML operations consolidated at Sultanpur expected to drive cost efficiencies starting Q3-Q4 (Page 7).

- Overall volume growth target of around 12% is aimed, with potential to maintain this in the near term. - Paint volumes grew by about 12% in H1 FY26; Q3 expected to be similar to Q2, while Q4 anticipates double-digit growth. - Food and FMCG segment targeting 15%-20% growth, supported by new Panipat plant operations starting in Q4. - Pharma segment expected to grow from Rs. 35-40 crores in current year to Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31. - Pharma volumes and revenue expected to increase with brownfield expansion and new facility coming online FY27. - EBITDA per kg for food and FMCG expected steady at Rs. 70-75; pharma EBITDA per kg around Rs. 100-120. - North plant to reduce supply cost/time, aiding growth and offsetting slight price realization pressure in food/FMCG. - Overall sales value growth forecasted in the 12-15% range.

- Food and FMCG segment EBITDA per kg expected to be steady around Rs. 70-75 (down from Rs. 75-80 earlier), with volume growth offsetting slight dip in realizations. - Overall volume growth target maintained at about 12% for the full year, driven by pharma and food & FMCG segments. - EBITDA margin improvements anticipated to sustain at around 40-41% in H2 FY26, up from 37.6% last year. - Pharma segment revenue expected to rise significantly: Rs. 35-40 crores in FY26, targeting Rs. 55-60 crores next year, with long-term potential of Rs. 150-180 crores by FY30/31. - EBITDA per kg for pharma segment estimated around Rs. 100-120. - EBITDA per kg company-wide expected to stabilize at Rs. 40-42 in H2, improving from around Rs. 37.6 last year. - CAPEX planned around Rs. 100-105 crores for FY26, supporting capacity expansions, especially in pharma.

- More than 50 pharma companies have visited Mold-Tek Packaging's premises. - Around 20-25 of these companies have started buying in small or medium quantities. - None of these clients contribute more than 10-20% individually; sales are well spread out. - For bottles and caps, the company has 7-8 decent-size clients supplying around Rs. 25-30 lakhs per month each. - Remaining 30 client approvals are done, but commercial trials will take a few more quarters. - Two strategic pharma customers have started giving small pilot orders worth around Rs. 70-80 lakhs over 2-3 months with expected ramp-up in Q4. - The company has signed one major contract at Panipat for food and FMCG, expected to add Rs. 4-5 crores turnover next financial year. - No significant export order cancellations due to tariffs; export levels remain negligible around Rs. 2-3 crores annually.